Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001628280-25-021055
Filing Date
2025-04-30
Accepted
2025-04-30 16:06:12
Documents
17
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A ovid-20241231.htm   iXBRL 10-K/A 418091
  Complete submission text file 0001628280-25-021055.txt   980651

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20241231.xsd EX-101.SCH 3506
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ovid-20241231_def.xml EX-101.DEF 2660
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20241231_lab.xml EX-101.LAB 139403
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20241231_pre.xml EX-101.PRE 75049
19 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20241231_htm.xml XML 15632
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

EIN.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38085 | Film No.: 25894979
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)